SavedAdd your journal

Journals / MN Kardiyoloji / 2010 / Cilt: 17 - Sayı: 3

Psoriasis and cardiovascular involvement

Psöriazis ve kardiyovasküler tutulum

Asuman BİÇER
Nurcan BAŞAR
Sani Namık MURAT
Pages
213–218
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we will mention about the increased incidence of cardiovascular risk factors and frequent abnormalities of cardiovascular system seen in psoriasis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Psoriasis is a chronic inflammatory skin disorder with unknown origin and characterized by erythematous plaques covered by silvery-white scales, generally at the elbows, knees, scalp, umblicus and lumber area.
📊
Key Findings & Data:Many systemic diseases including cardiovascular disturbances have been described in psoriatic patients.
💡
Conclusion & Impact:In this review, we will mention about the increased incidence of cardiovascular risk factors and frequent abnormalities of cardiovascular system seen in psoriasis.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Psoriasis is a chronic inflammatory skin disorder with unknown origin and characterized by erythematous plaques covered by silvery-white scales, generally at the elbows, knees, scalp, umblicus and lumber area. Many systemic diseases including cardiovascular disturbances have been described in psoriatic patients. In this review, we will mention about the increased incidence of cardiovascular risk factors and frequent abnormalities of cardiovascular system seen in psoriasis.

Özet

Psöriyazis, genellikle diz, dirsek, saçlı deri, umblikus ve lomber alanda ortaya çıkan gümüşi beyaz renkli kepeklenmelerle kaplı eritemli plaklarla karakterize, nedeni bilinmeyen kronik, enflamatuar deri hastalığıdır. Psöriaziste kardiyovasküler bozukluklar dahil çok sayıda sistemik hastalık tanımlanmıştır. Bu derlemede psöriazis hastalarında artmış olan kardiyovasküler risk faktörlerine ve sıklıkla izlenen kardiyovasküler anormalliklere değinilecektir.

🔖

Cite This Article

BİÇER, A., BAŞAR, N., MURAT, S. N. (2010). Psoriasis and cardiovascular involvement. MN Kardiyoloji, Cilt: 17 - Sayı: 3, 213–218. https://ajindex.com/articles/297500

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Henseler T, Christophers E. Psöriazis of early and late on - set: characterization of two types of psöriazis vulgaris. J Am Acad Dermatol 1985;13(3):450-6
  2. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141(12):1537-41 3. Das RP, Jain AK, Ramesh V. Current concepts in the pathogenesis of psoriasis. Indian J Dermatol 2009;54 (1):7-12
  3. Saricaoglu H, Güllülü S, Bülbül Baskan E, Cordan J, Tunali S. Echocardiographic findings in subjects with psoriatic arthropathy. J Eur Acad Dermatol Venereol 2003;17 (4):414-7
  4. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 1982;62:229-36
  5. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol 1993;29:428-34
  6. Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients-an analysis of 1019 HLA-Cand HLA-B-typed patients. J Invest Dermatol 2006;126: 740-5
  7. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd. Biology of tumor necrosis factor- alpha implications for psoriasis. Exp Dermatol 2004; 13:193-222
  8. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis fac tor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11
  9. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81:627-35
  10. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-95
  11. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50(3):416-30
  12. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190 (1):1-9
  13. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005;5:124-39
  14. Griffiths CE, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150(Suppl. 67):11-23